1-[3-(三氟甲基)苯基]环丁烷-1-羧酸 | 151157-58-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[3-(三氟甲基)苯基]环丁烷-1-羧酸
• 中文别名: 1-（3-（三氟甲基）苯基）环丁烷-1-羧酸
• 英文名称: 1-(3-(trifluoromethyl)phenyl)cyclobutane-1-carboxylic acid
• 英文别名: 1-(3-trifluoromethylphenyl)cyclobutane carboxylic acid；1-[3-(Trifluoromethyl)phenyl]cyclobutane-1-carboxylic acid
• CAS: 151157-58-3
• 化学式: C₁₂H₁₁F₃O₂
• mdl: MFCD11037070
• 分子量: 244.213
• InChiKey: OEIXASDDYLPZFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-[3-(Trifluoromethyl)phenyl]cyclobutane-1-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-[3-(Trifluoromethyl)phenyl]cyclobutane-1-carboxylic acid
CAS number: 151157-58-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H11F3O2
Molecular weight: 244.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-[3-(三氟甲基)苯基]环丁烷-1-羧酸 在 4-二甲氨基吡啶 、 三溴化硼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(5'-chloro-2',4'-dihydroxyphenyl)-1-(3-trifluoromethylphenyl)cyclobutanecarboxyamide
  参考文献：
  名称：

  Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)

  摘要：

  N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with la reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.

  DOI：

  10.1021/acs.jmedchem.5b00702
• 作为产物：
  描述：

  1-[3-(三氟甲基)苯基]环丁烷-1-腈 在 盐酸 、 sodium hydroxide 、 双氧水 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 1-[3-(三氟甲基)苯基]环丁烷-1-羧酸
  参考文献：
  名称：

  Tetraisoquinoline compounds which have useful pharmaceutical utility

  摘要：

  四氢异喹啉化合物的化学式为I ##STR1##，其药用盐和亲脂性酯具有镇痛作用，并可用于治疗精神病、帕金森病、莱施-尼恩综合征、注意力缺陷障碍或认知障碍，以及缓解药物依赖或迟发性运动障碍。

  公开号：

  US05519034A1

文献信息

• Tetraisoquinoline compounds which have useful pharmaceutical utility
  申请人：The Boots Company PLC

  公开号：US05519034A1

  公开（公告）日：1996-05-21

  Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts and lipophilic ester thereof have utility as analgesics and in the treatment of psychoses, Parinson's disease, Lesch-Nyan syndrome, attention deficit disorder or cognitive impairment or in the relief of drug dependence or tardive dyskinesia.

  四氢异喹啉化合物的化学式为I ##STR1##，其药用盐和亲脂性酯具有镇痛作用，并可用于治疗精神病、帕金森病、莱施-尼恩综合征、注意力缺陷障碍或认知障碍，以及缓解药物依赖或迟发性运动障碍。
• SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：The Boots Company PLC

  公开号：EP0618900A1

  公开（公告）日：1994-10-12
• US5519034A
  申请人：——

  公开号：US5519034A

  公开（公告）日：1996-05-21
• [EN] SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：THE BOOTS COMPANY PLC

  公开号：WO1993013073A1

  公开（公告）日：1993-07-08

  (EN) Tetrahydroisoquinoline compounds of formula (I) and pharmaceutically acceptable salts thereof, in which: R1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, nitro, cyano, polyhaloalkyl, polyhaloalkoxy, phenyl (optionally substituted by one or more of halo, alkyl or alkoxy), or R1 is optionally alkylated carbamoyl; R2 represents an aliphatic group optionally substituted by hydroxy or alkoxy; E represents an alkylene chain optionally substitued by one or more alkyl groups; and G represents phenyl or phenyl substituted by one or more of alkyl, alkoxy, halo, hydroxy, polyhaloalkyl, polyhaloalkoxy, cyano, alkylthio, alkylsulphinyl, alkylsulphonyl, phenyl (optionally substituted by one or more of halo, alkyl or alkoxy), optionally alkylated carbamoyl, or G represents a phenyl ring having fused thereto a heterocyclic or aromatic carbocyclic ring; and O^_-acylated derivatives thereof which provide lipophilic esters have utility in analgesia and in the treatment of psychoses (e.g. schizophrenia), Parkinson's disease, Lesch-Nyan syndrome, attention deficit disorder or cognitive impairment or in the relief of drug dependence or tardive dyskinesia.(FR) La présente invention se rapporte à des composés de tétrahydroisoquinoléine de formule (I), et à leurs sels pharmaceutiquement acceptables. Dans la formule, R1 représente un ou plusieurs remplaçants sélectionnés parmi H, halo, hydroxy, alcoyle (éventuellement substitué par hydroxy), alcoxy, alcoylthio, alcoylsulfinyle, alcoyle-sulfonyle, nitro, cyano, polyhaloalcoyle, polyhaloalcoyloxy, phényle (éventuellement substitué par un ou plusieurs remplaçants sélectionnés parmi halo, alcoyle, ou alcoxy), ou R1 est un carbamoyle éventuellement alcoylé; R2 représente un groupe aliphatique éventuellement substitué par hydroxy ou alcoxy; E représente une chaîne alkylène éventuellement substituée par un ou plusieurs groupes alcoyle; et G représente un phényle ou un phényle substitué par un ou plusieurs alcoyle, alcoxy, halo, hydroxy, polyhaloalcoyle, polyhaloalcoxy, cyano, alcoylthio, alcoylsulfinyle, alcoylsulfonyle, phényle (éventuellement substitué par un ou plusieurs remplaçants sélctionnés parmi halo, alcoyle ou alcoxy), carbamoyle, éventuellement alcoylé, ou G représente un cycle phénylique ayant fusionné avec un cycle carbocyclique hétérocyclique ou aromatique. L'invention concerne également les dérivés O^_-acylatés desdits composés qui produisent des esters lipophiles. Les composés de l'invention sont destinés à être utilisés pour l'analgésie et pour le traitement des psychoses (par exemple la schizophrénie), la maladie de Parkinson, le syndrome de Lesch-Nyan, le trouble déficitaire de l'attention ou un déficit cognitif ou pour soulager en cas de toxicomanie ou de dyskinésies tardives.
• Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)
  作者：Wu He、Bin Zhou、Weijia Liu、Meizi Zhang、Zhenhua Shen、Zhifu Han、Qingwei Jiang、Qinghua Yang、Chuanjun Song、Ruiyong Wang、Tianhui Niu、Shengna Han、Lirong Zhang、Jie Wu、Feima Guo、Renbin Zhao、Wenquan Yu、Jijie Chai、Junbiao Chang

  DOI：10.1021/acs.jmedchem.5b00702

  日期：2015.9.24

  N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with la reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.